Fulcrum Therapeutics Inc (NASDAQ:FULC)

4.91
Delayed Data
As of Jul 01
 +0.01 / +0.20%
Today’s Change
3.21
Today|||52-Week Range
33.10
-72.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$210.0M

Company Description

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Contact Information

Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge Massachusetts 02139
P:(617) 651-8851
Investor Relations:

Employees

Shareholders

Other institutional59.19%
Mutual fund holders25.03%
Individual stakeholders18.19%

Top Executives

Bryan E StuartPresident, Chief Executive Officer, COO & Director
Esther RajaveluChief Financial Officer & Treasurer
Christopher J MorabitoChief Medical Officer
Mani SundararajanSenior Vice President-Technical Operations
Leslie LeinwandScientific Advisory Board